NR 565 Advanced Pharmacology
NR 565 Advanced Pharmacology
Chamberlain Final Exam Comprehensive
Practice Review: 200 High-Yield Questions
with Verified Answers and Detailed
Rationales (2026–2027 Edition) | Graded
A+
Content Domains Covered:
• Pharmacokinetics and Pharmacodynamics
• Pharmacogenomics and CYP450 Drug Interactions
• Cardiovascular Pharmacology
• Endocrine Pharmacology
• Thyroid and Endocrine Disorders
• Respiratory Pharmacology
• CNS and Psychiatric Pharmacology
• Gastrointestinal Pharmacology
• Anti-infectives and Immune Modulators
• Special Populations and Renal/Hepatic Dosing
Purpose:
This practice review is designed to support graduate nursing students preparing for
the NR 565 Advanced Pharmacology final exam. It emphasizes clinical reasoning,
drug mechanism of action, adverse effects, monitoring parameters, and patient
education.
,Section 1: Pharmacokinetics & Pharmacodynamics (Q1–Q10)
Q1. A patient asks how a medication taken by mouth produces an effect in
the body. The APRN explains that the process by which a drug is absorbed,
distributed, metabolized, and excreted is known as:
A) Pharmacodynamics
B) Pharmacotherapeutics
C) Pharmacokinetics
D) Pharmacogenomics
Answer: C — Pharmacokinetics is the study of drug movement throughout the
body, including absorption, distribution, metabolism, and excretion (ADME).
Pharmacodynamics is what the drug does to the body.
Q2. A drug that binds to a receptor and produces a response that is less than
that of a full agonist, even at maximal concentrations, is known as a:
A) Partial agonist
B) Inverse agonist
C) Competitive antagonist
D) Noncompetitive antagonist
Answer: A — A partial agonist has lower efficacy than a full agonist. It binds to
and activates a receptor but cannot produce a maximal response, even when
all receptors are occupied.
Q3. An APRN is prescribing a medication that is known to be a CYP450
enzyme inducer. What effect will this have on other medications metabolized
by that enzyme pathway?
A) Increased serum levels of the other medications, potentially leading to
toxicity
B) Decreased serum levels of the other medications, potentially leading to
therapeutic failure
C) No effect on serum levels of the other medications
D) Prolonged half-life of the other medications
,Answer: B — CYP450 inducers increase the metabolic activity of liver enzymes,
leading to faster breakdown of medications metabolized through that pathway.
This results in decreased serum concentrations and potential loss of therapeutic
effect.
Q4. Which organ is the primary site for drug metabolism?
A) Kidneys
B) Liver
C) Lungs
D) Spleen
Answer: B — The liver contains the cytochrome P450 enzyme system essential
for drug metabolism. The kidneys are the main organs for drug excretion. The
lungs excrete volatile gases but are not the primary site of metabolism.
Q5. What does the term "bioavailability" refer to in pharmacokinetics?
A) The amount of drug excreted in the urine
B) The percentage of an administered dose of unchanged drug that reaches the
systemic circulation
C) The half-life of the drug in the body
D) The volume of fluid into which the drug distributes
Answer: B — Bioavailability measures the extent and rate of drug entry into
systemic circulation. Renal clearance refers to drug excretion. Half-life is the
time for drug concentration to decrease by half.
Q6. A drug that binds to a receptor and produces a biological response is
called a(n):
A) Antagonist
B) Agonist
C) Partial agonist
D) Inverse agonist
Answer: B — An agonist binds to a receptor and activates it to produce a
biological response. An antagonist binds but blocks the response. A partial
agonist produces a weaker response than a full agonist.
Q7. The time required for the plasma concentration of a drug to decrease by
50% is called:
A) Onset of action
B) Duration of action
, C) Half-life
D) Bioavailability
Answer: C — Half-life is the time required for the plasma concentration of a
drug to decrease by 50%. Onset of action is the time to therapeutic effect.
Duration is how long the effect lasts.
Q8. The therapeutic index (TI) is defined as:
A) The ratio of toxic dose to therapeutic dose
B) The ratio of therapeutic dose to toxic dose
C) The dose required to produce a therapeutic effect
D) The dose required to produce a toxic effect
Answer: A — The therapeutic index (TI) is the ratio of the toxic dose to the
therapeutic dose. A narrow TI indicates a small margin of safety.
Q9. A 68-year-old patient with chronic kidney disease (eGFR 30 mL/min) is
prescribed a medication primarily eliminated unchanged by the kidneys.
Compared to a patient with normal renal function, this patient will most
likely require which dosing adjustment?
A) Higher dose with more frequent administration
B) Lower dose and/or less frequent administration
C) Same dose with increased fluid intake
D) No adjustment because renal function decline is expected with age
Answer: B — Impaired renal clearance leads to drug accumulation and
increased toxicity risk; standard practice is dose reduction, extended dosing
intervals, or both based on the drug's therapeutic index and severity of
impairment.
Q10. A patient with cirrhosis and portacaval shunting is prescribed a drug
with a high hepatic extraction ratio. Which change in oral bioavailability is
most expected?
A) Decreased oral bioavailability
B) Increased oral bioavailability
C) Decreased half-life
D) Increased renal clearance
Answer: B — High extraction ratio drugs undergo extensive first-pass
metabolism. Cirrhosis with portacaval shunting allows blood to bypass the liver,
NR 565 Advanced Pharmacology
Chamberlain Final Exam Comprehensive
Practice Review: 200 High-Yield Questions
with Verified Answers and Detailed
Rationales (2026–2027 Edition) | Graded
A+
Content Domains Covered:
• Pharmacokinetics and Pharmacodynamics
• Pharmacogenomics and CYP450 Drug Interactions
• Cardiovascular Pharmacology
• Endocrine Pharmacology
• Thyroid and Endocrine Disorders
• Respiratory Pharmacology
• CNS and Psychiatric Pharmacology
• Gastrointestinal Pharmacology
• Anti-infectives and Immune Modulators
• Special Populations and Renal/Hepatic Dosing
Purpose:
This practice review is designed to support graduate nursing students preparing for
the NR 565 Advanced Pharmacology final exam. It emphasizes clinical reasoning,
drug mechanism of action, adverse effects, monitoring parameters, and patient
education.
,Section 1: Pharmacokinetics & Pharmacodynamics (Q1–Q10)
Q1. A patient asks how a medication taken by mouth produces an effect in
the body. The APRN explains that the process by which a drug is absorbed,
distributed, metabolized, and excreted is known as:
A) Pharmacodynamics
B) Pharmacotherapeutics
C) Pharmacokinetics
D) Pharmacogenomics
Answer: C — Pharmacokinetics is the study of drug movement throughout the
body, including absorption, distribution, metabolism, and excretion (ADME).
Pharmacodynamics is what the drug does to the body.
Q2. A drug that binds to a receptor and produces a response that is less than
that of a full agonist, even at maximal concentrations, is known as a:
A) Partial agonist
B) Inverse agonist
C) Competitive antagonist
D) Noncompetitive antagonist
Answer: A — A partial agonist has lower efficacy than a full agonist. It binds to
and activates a receptor but cannot produce a maximal response, even when
all receptors are occupied.
Q3. An APRN is prescribing a medication that is known to be a CYP450
enzyme inducer. What effect will this have on other medications metabolized
by that enzyme pathway?
A) Increased serum levels of the other medications, potentially leading to
toxicity
B) Decreased serum levels of the other medications, potentially leading to
therapeutic failure
C) No effect on serum levels of the other medications
D) Prolonged half-life of the other medications
,Answer: B — CYP450 inducers increase the metabolic activity of liver enzymes,
leading to faster breakdown of medications metabolized through that pathway.
This results in decreased serum concentrations and potential loss of therapeutic
effect.
Q4. Which organ is the primary site for drug metabolism?
A) Kidneys
B) Liver
C) Lungs
D) Spleen
Answer: B — The liver contains the cytochrome P450 enzyme system essential
for drug metabolism. The kidneys are the main organs for drug excretion. The
lungs excrete volatile gases but are not the primary site of metabolism.
Q5. What does the term "bioavailability" refer to in pharmacokinetics?
A) The amount of drug excreted in the urine
B) The percentage of an administered dose of unchanged drug that reaches the
systemic circulation
C) The half-life of the drug in the body
D) The volume of fluid into which the drug distributes
Answer: B — Bioavailability measures the extent and rate of drug entry into
systemic circulation. Renal clearance refers to drug excretion. Half-life is the
time for drug concentration to decrease by half.
Q6. A drug that binds to a receptor and produces a biological response is
called a(n):
A) Antagonist
B) Agonist
C) Partial agonist
D) Inverse agonist
Answer: B — An agonist binds to a receptor and activates it to produce a
biological response. An antagonist binds but blocks the response. A partial
agonist produces a weaker response than a full agonist.
Q7. The time required for the plasma concentration of a drug to decrease by
50% is called:
A) Onset of action
B) Duration of action
, C) Half-life
D) Bioavailability
Answer: C — Half-life is the time required for the plasma concentration of a
drug to decrease by 50%. Onset of action is the time to therapeutic effect.
Duration is how long the effect lasts.
Q8. The therapeutic index (TI) is defined as:
A) The ratio of toxic dose to therapeutic dose
B) The ratio of therapeutic dose to toxic dose
C) The dose required to produce a therapeutic effect
D) The dose required to produce a toxic effect
Answer: A — The therapeutic index (TI) is the ratio of the toxic dose to the
therapeutic dose. A narrow TI indicates a small margin of safety.
Q9. A 68-year-old patient with chronic kidney disease (eGFR 30 mL/min) is
prescribed a medication primarily eliminated unchanged by the kidneys.
Compared to a patient with normal renal function, this patient will most
likely require which dosing adjustment?
A) Higher dose with more frequent administration
B) Lower dose and/or less frequent administration
C) Same dose with increased fluid intake
D) No adjustment because renal function decline is expected with age
Answer: B — Impaired renal clearance leads to drug accumulation and
increased toxicity risk; standard practice is dose reduction, extended dosing
intervals, or both based on the drug's therapeutic index and severity of
impairment.
Q10. A patient with cirrhosis and portacaval shunting is prescribed a drug
with a high hepatic extraction ratio. Which change in oral bioavailability is
most expected?
A) Decreased oral bioavailability
B) Increased oral bioavailability
C) Decreased half-life
D) Increased renal clearance
Answer: B — High extraction ratio drugs undergo extensive first-pass
metabolism. Cirrhosis with portacaval shunting allows blood to bypass the liver,
